Cited by 405SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingCOVID-19 epidemiological studies

The DOI matches its Crossref record; 12 of the 14 references it cites were found in a registry or an index.

Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

Open access

Xu, Xin, Sun, Jian, Nie, Sheng, Li, Huiyuan, Kong, Yaozhong, Liang, Min, Hou, Jinlin, Huang, Xianzhong, Li, Dongfeng, Ma, Tean, Peng, Jiaqing, Gao, Shikui, Shao, Yong, Zhu, Hong, Lau, Johnson Yiu-Nam, Wang, Guangyu, Xie, Chunbao, Jiang, Li, Huang, Ailong, Yang, Zhenglin, Zhang, Kang, Hou, Fan Fan·2020·Nature Medicine

DOI 10.1038/s41591-020-0949-6

Open this paper in CoChat — free account Open PDF

Abstract

Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5-4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5-2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41591-020-0949-6

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citation
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected pneumonia in Wuhan, China
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Self-citation
SARS-CoV-2 Infection in Children
Lü, X., Zhang, L., Du, H. N., Zhang, J., Li, Y. Y., Qu, J., Zhang, W., Wang, Y., Bao, S., Li, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2005073 · Cited by 2,423
The Empirical Distribution Function with Arbitrarily Grouped, Censored and Truncated Data
Turnbull, B. W. (1976) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/j.2517-6161.1976.tb01597.x · Cited by 1,835
Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened Among Close Contacts in Nanjing, China
Hu, Z., Song, C., Xu, C., Jin, G., Chen, Y., Xu, X., Ma, H., Chen, W., Lin, Y., Zheng, Y., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1661-4 · Cited by 1,429
Self-citation
A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment
Munster, V. J., Koopmans, M., van Doremalen, N., van Riel, D. A. J., & de Wit, E. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2000929 · Cited by 1,418

Show all 14 references

Sorted by citations

Items 101–200 of 405

Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study
Xu, X. P., Nie, S., Wang, Y., Long, Q., Zhu, H., Zhang, X., Sun, J., Zeng, Q., Zhao, J., Liu, L., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00611-6 · Cited by 28
Self-citation
Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study
Барчук, А. А., Skougarevskiy, D., Титаев, К. Д., Shirokov, D., Raskina, Y. V., Novkunkskaya, A., Talantov, P., Isaev, A. A., Pomerantseva, E. A., Zhikrivetskaya, S. O., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92206-y · Cited by 27
Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany
Erber, J., Kappler, V., Haller, B., Mijočević, H., Galhoz, A., da Costa, C. P., Gebhardt, F. E., Graf, N., Hoffmann, D., Thaler, M., et al. (2020) · Emerging infectious diseases · doi:10.3201/eid2803.204436 · Cited by 29
SARS-CoV-2 Seroprevalence among a Southern U.S. Population Indicates Limited Asymptomatic Spread under Physical Distancing Measures
Barzin, A., Schmitz, J. L., Rosin, S. P., Sirpal, R., Almond, M. A., Robinette, C., Wells, S., Hudgens, M. G., Olshan, A. F., Deen, S., et al. (2020) · mBio · doi:10.1128/mbio.02426-20 · Cited by 25
Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis
Nopsopon, T., Kittrakulrat, J., Takkavatakarn, K., Eiamsitrakoon, T., Kanjanabuch, T., & Pongpirul, K. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009156 · Cited by 27
Estimating the transmission advantage of the D614G mutant strain of SARS-CoV-2, December 2019 to June 2020
Leung, K. S. M., Pei, Y., Leung, G. M., Lam, T. T., & Wu, J. T. K. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.49.2002005 · Cited by 27
SARS-CoV-2 seroprevalence among healthcare workers
Wiggen, T. D., Bohn, B., Ulrich, A. K., Stovitz, S. D., Strickland, A. J., Naumchik, B. M., Walsh, S., Smith, S. M., Baumgartner, B., Kline, S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266410 · Cited by 30
Seroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis
Hajissa, K., Islam, M. A., Hassan, S. A., Zaidah, A. R., Ismail, N., & Mohamed, Z. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127257 · Cited by 28
SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria
Kolawole, O. M., Tomori, O., Agbonlahor, D. E., Ekanem, E., Bakare, R. A., Abdulsalam, N., Okojie, O. H., Braide, E. I., Uzochukwu, B. S. C., Rafindadi, A., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.36053 · Cited by 26
Jobs, Housing, and Mask Wearing: Cross-Sectional Study of Risk Factors for COVID-19
van den Broek‐Altenburg, E. M., Atherly, A. J., Diehl, S. A., Gleason, K. M., Hart, V. C., MacLean, C. D., Barkhuff, D., Levine, M. A., & Carney, J. K. (2020) · JMIR Public Health and Surveillance · doi:10.2196/24320 · Cited by 28
Seroprevalence of hospital staff in a province with zero COVID-19 cases
Nopsopon, T., Pongpirul, K., Chotirosniramit, K., Jakaew, W., Kaewwijit, C., Kanchana, S., & Hiransuthikul, N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0238088 · Cited by 24
Low seroprevalence of COVID-19 in Lao PDR, late 2020
Virachith, S., Pommelet, V., Calvez, E., Khounvisith, V., Sayasone, S., Kounnavong, S., Mayxay, M., Xangsayarath, P., Temmam, S., Éloit, M., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100197 · Cited by 21
Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based studyPreprint
Richard, A., Wisniak, A., Perez‐Saez, J., Garrison‐Desany, H. M., Petrović, D., Piumatti, G., Baysson, H., Picazio, A., Pennacchio, F., Ridder, D. D., et al. (2020) · medRxiv · doi:10.1101/2020.12.16.20248180 · Cited by 25
SARS-CoV-2 reinfection in two patients who have recovered from COVID-19
Zhang, K., Lau, J. Y., Yang, L., & Ma, Z. (2020) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaa031 · Cited by 24
Self-citation
Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic
Sughayer, M. A., Mansour, A. H., Nuirat, A. A., Souan, L., Ghanem, M. A., Siag, M., & Alhassoon, S. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.059 · Cited by 24
Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Random Sample of Inhabitants of the Katowice Region, Poland
Zejda, J. E., Brożek, G. M., Kowalska, M., Barański, K., Kaleta-Pilarska, A. P., Nowakowski, A., Xia, Y., & Buszman, P. E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18063188 · Cited by 24
Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates
Bhattacharyya, R., Kundu, R., Bhaduri, R., Ray, D., Beesley, L. J., Salvatore, M., & Mukherjee, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-89127-1 · Cited by 23
Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic
Javadinia, S. A., Ariamanesh, M., Nabavifard, M., Porouhan, P., PeyroShabany, B., Fazilat‐Panah, D., Hatami, F., Ghasemi, A., Lyman, G. H., Welsh, J. S., et al. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1995742 · Cited by 23
The role of serum specific- SARS-CoV-2 antibody in COVID-19 patients
Chen, H., Zhang, X., Liu, W., Xue, M., Liao, C., Huang, Z., Hu, H., & Sun, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107325 · Cited by 24
Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra
Royo, C., Vilanova, D., Lopez, J., Arroyo, V., Pons, M., Francisco, G., Carrasco, M. G., Piqué, J. M., Sanz, S., Dobaño, C., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100119 · Cited by 21
Seroprevalence and asymptomatic carrier status of SARS-CoV-2 in Wuhan City and other places of China
Duan, S., Zhou, M., Zhang, W., Shen, J., Qi, R., Qin, X., Yu, H., Zhou, C., Hu, Q., & Yu, X. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008975 · Cited by 22
The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic
Good, M. F., & Hawkes, M. (2020) · mBio · doi:10.1128/mbio.02617-20 · Cited by 21
Frequency of COVID-19 IgG Antibodies among Special Police Squad Lahore, Pakistan
Chughtai, O. R., Batool, H., Khan, M. D., & Chughtai, A. (2020) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2020.07.735 · Cited by 21
CD8 T cell epitope generation toward the continually mutating SARS-CoV-2 spike protein in genetically diverse human population: Implications for disease control and prevention
Guo, E., & Guo, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239566 · Cited by 21
Prospective surveillance study in a 1,400‐bed university hospital: COVID‐19 exposure at home was the main risk factor for SARS‐CoV‐2 point seroprevalence among hospital staff
Bahrs, C., Kimmig, A., Weis, S., Ankert, J., Hagel, S., Maschmann, J., Stallmach, A., Steiner, A., Bauer, M. W., Behringer, W., et al. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14041 · Cited by 19
An investigation of testing capacity for evaluating and modeling the spread of coronavirus disease
Zhan, C., Chen, J., & Zhang, H. (2021) · Information Sciences · doi:10.1016/j.ins.2021.01.084 · Cited by 21
Nationwide seroprevalence of antibodies to SARS-CoV-2 in asymptomatic population in South Korea: a cross-sectional study
Nah, E., Cho, S., Park, H., Hwang, I., & Cho, H. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049837 · Cited by 21
Asymptomatic COVID-19 in South Africa – implications for the control of transmission
Paleker, M., Tembo, Y., Davies, M.-A., Mahomed, H., Pienaar, D., Madhi, S. A., & McCarthy, K. (2021) · Public Health Action · doi:10.5588/pha.20.0069 · Cited by 21
High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for herd immunity!
Núñez-Zapata, S. F., Benites-Peralta, B., Mayta‐Tristán, P., & Rodriguez-Morales, A. J. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.022 · Cited by 21
Performance assessment of seven SARS‐CoV‐2 IgG enzyme‐linked immunosorbent assays
Deshpande, K., Ullas, P. T., Kaduskar, O., Vijay, N., Rakhe, A., Vidhate, S., Khutwad, K., Deshpande, G. R., Tilekar, B. N., Saka, S., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27251 · Cited by 21
Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
Al-Abri, S., Wahaibi, A. S. A., Al-Kindi, H., Kurup, P. J., Al-Maqbali, A., Almayahi, Z. K., Al-Tobi, M. H., Al-Katheri, S. H., Albusaidi, S., Al-Sukaiti, M. H., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.062 · Cited by 21
A Prospective Study of Risk Factors Associated with Seroprevalence of SARS-CoV-2 Antibodies in Healthcare Workers at a Large UK Teaching Hospital
Cooper, D. J., Lear, S. E., Watson, L. P. E., Shaw, A. S., Ferris, M., Döffinger, R., Bousfield, R., Sharrocks, K., Weekes, M. P., Warne, B., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2022.08.030 · Cited by 20
Animal Models of COVID-19 II. Comparative Immunology
Veenhuis, R. T., & Zeiss, C. J. (2021) · ILAR Journal · doi:10.1093/ilar/ilab010 · Cited by 21
Representative estimates of COVID-19 infection fatality rates from four locations in India: cross-sectional study
Cai, R., Novosad, P. M., Tandel, V., Asher, S., & Malani, A. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050920 · Cited by 20
Reconciling epidemiological models with misclassified case-counts for SARS-CoV-2 with seroprevalence surveys: A case study in Delhi, IndiaPreprint
Bhattacharyya, R., Bhaduri, R., Kundu, R., Salvatore, M., & Mukherjee, B. (2020) · medRxiv · doi:10.1101/2020.07.31.20166249 · Cited by 20
Seroprevalence of SARS-CoV-2 Antibodies in Adults and Healthcare Workers in Southern Italy
Napolitano, F., Giuseppe, G. D., Montemurro, M. V., Molinari, A. M., Donnarumma, G., Arnese, A., Pavía, M., & Angelillo, I. F. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094761 · Cited by 19
Seroprevalence of SARS-CoV-2 antibody among individuals aged above 15 years and residing in congregate settings in Dire Dawa city administration, Ethiopia
Shaweno, T., Abdulhamid, I., Bezabih, L., Teshome, D., Derese, B., Tafesse, H., & Shaweno, D. (2021) · Tropical Medicine and Health · doi:10.1186/s41182-021-00347-7 · Cited by 19
Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK
Amirthalingam, G., Whitaker, H., Brooks, T. J. G., Brown, K. E., Höschler, K., Linley, E., Borrow, R., Brown, C. S., Watkins, N. A., Roberts, D. J., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2707.203167 · Cited by 19
COVID-19 seroprevalence among hospital staff and preprocedural patients in Thai community hospitals: a cross-sectional study
Nopsopon, T., Pongpirul, K., Chotirosniramit, K., & Hiransuthikul, N. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046676 · Cited by 19
Potent neutralizing equine antibodies raised against recombinant SARS-CoV-2 spike protein for COVID-19 passive immunization therapyPreprint
da Cunha, L. E. R., Stolet, A. A., Strauch, M. A., Pereira, V. A. R., Dumard, C. H., Gomes, A. M. O., Souza, P. N. C., Fonseca, J. G. D. S., de Pontes, F. E., Meirelles, L. G. R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.17.254375 · Cited by 21
Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France
Dimeglio, C., Hérin, F., Miédougé, M., Cambus, J., Abravanel, F., Mansuy, J., Soulat, J.-M., & Izopet, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.09.035 · Cited by 19
COVID-19 seroprevalence in Pakistan: a cross-sectional study
Ahmad, A. M., Shahzad, K., Masood, M., Umar, M., Abbasi, F., & Hafeez, A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055381 · Cited by 18
Immunogenicity and safety of an inactivated SARS‐CoV‐2 vaccine in people living with HIV: A cross‐sectional study
Cai, S., Liao, G., Yu, T., Gao, Q., Zou, L., Zhang, H., Xu, X., Chen, J., Lu, A., Wu, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27872 · Cited by 18
Self-citation
Plasma cell-free DNA promise monitoring and tissue injury assessment of COVID-19
Jin, X., Wang, Y., Xu, J., Li, Y., Cheng, F., Luo, Y., Zhou, H., Lin, S., Xiao, F., Zhang, L., et al. (2023) · Molecular Genetics and Genomics · doi:10.1007/s00438-023-02014-4 · Cited by 19
Self-citation
Serological antibody testing in the COVID-19 pandemic: their molecular basis and applications
Jiang, J.-C., & Zhang, Y. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200744 · Cited by 19
Phytoremediation for a sustainable future: Integrating plant based strategies in soil and wastewater remediation
Sahoo, A., Chhotaray, S. P., Meher, I., Behera, S. P., Pal, A., Meena, M., Swapnil, P., Yadav, A., & Bhardwaj, R. (2025) · Bioresource Technology Reports · doi:10.1016/j.biteb.2025.102266 · Cited by 21
The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19
Qin, X., Shen, J., Dai, E., Li, H., Tang, G., Zhang, L., Hou, X., Lu, M., Wu, X., Duan, S., et al. (2021) · BMC Immunology · doi:10.1186/s12865-021-00404-0 · Cited by 17
Self-citation
Diagnosed and Undiagnosed COVID-19 in US Emergency Department Health Care Personnel: A Cross-sectional Analysis
Mohr, N. M., Harland, K. K., Krishnadasan, A., Eyck, P. T., Mower, W. R., Willey, J., Chisolm‐Straker, M., Lim, S. C., McDonald, L. C., Kutty, P. K., et al. (2020) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2020.12.007 · Cited by 17
Driving force of COVID-19 among people living with HIV in Wuhan, China
Guo, W., Ming, F., Dong, Y., Zhang, Q., Liu, L., Gao, M., Zhang, X., Mo, P., Feng, Y., Tang, W., et al. (2022) · AIDS Care · doi:10.1080/09540121.2022.2052259 · Cited by 17
SARS-CoV-2 Seroprevalence in Lithuania: Results of National Population Survey
Šmigelskas, K., Petrikonis, K., Kasiulevičius, V., Kalèdiené, R., Jakaitienė, A., Kaselienė, S., Sauliūnė, S., Beržanskytė, A., & Stankūnas, M. (2021) · Acta medica Lituanica · doi:10.15388/amed.2020.28.1.2 · Cited by 13
Changes in Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Over Time in 10 Sites in the United States, March–August, 2020
Lim, T. W., Delorey, M. J., Bestul, N. C., Johannson, M. A., Reed, C., Hall, A. J., Fry, A. M., Edens, C., Semenova, V. A., Han, L., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab185 · Cited by 14
Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020
Tadese, E. B., Endris, A. A., Solomon, H., Alayu, M., Kebede, A., Eshetu, K., Teka, G., Eskinder, B., Ahmed, J., Abayneh, S., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.08.028 · Cited by 16
Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19
Yakoubi, A., & Dhafer, C. E. B. (2022) · Plasmonics · doi:10.1007/s11468-022-01754-0 · Cited by 16
Kinetics and performance of the Abbott architect SARS-CoV-2 IgG antibody assay
Hamilton, F., Muir, P., Attwood, M., Vipond, A. N. B., Vipond, B., Hopes, R., Moran, E., Maskell, N. A., Warwick, D., Albur, M., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.07.031 · Cited by 16
An indirect method to monitor the fraction of people ever infected with COVID-19: An application to the United States
Sánchez-Romero, M., di Lego, V., Prskawetz, A., & Queiroz, B. L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245845 · Cited by 14
Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study
Ladoire, S., Goussot, V., Redersdorff, E., Cueff, A., Ballot, E., Truntzer, C., Ayati, S., Bengrine-Lefèvre, L., Bremaud, N., Coudert, B. P., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.027 · Cited by 15
COVID-19 serology in nephrology healthcare workers
Reiter, T., Pajenda, S., Wagner, L., Gaggl, M., Atamaniuk, J., Holzer, B., Zimpernik, I., Gerges, D., Mayer, K. A., Aigner, C., et al. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01848-5 · Cited by 15
The high level of adherence to personal protective equipment in health care workers efficiently protects them from COVID-19 infection
Zangoue, M., Safari, H., Royce, S. G., Zangooie, A., Rezapour, H., Zangouei, A., & Fereidouni, M. (2021) · Work · doi:10.3233/wor-210634 · Cited by 15
Population-based sero-epidemiological investigation of the dynamics of SARS-CoV-2 infections in the Greater Accra Region of Ghana
Mensah, B. A., Ndong, I. C., Quashie, P. K., Guichet, E., Abuaku, B. K., Effah-Baafi, Y., Tapela, K., Asiedu, K., Appiedu-Addo, S. N. A., Obbeng, L. B., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25598-0 · Cited by 15
The role of serological testing in the SARS-CoV-2 outbreak
Mayne, E. S., Scott, L. E., Semete, B., Julsing, A., Jugwanth, S., Mampeule, N., David, A., Gededzha, M. P., Goga, A. E., Hardie, D. R., et al. (2020) · South African Medical Journal · doi:10.7196/samj.2020.v110i9.15098 · Cited by 15
Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020
Capai, L., Ayhan, N., Masse, S., Canarelli, J., Priet, S., Simeoni, M.-H., Charrel, R. N., de Lamballerie, X. N., & Falchi, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113569 · Cited by 17
SARS-COV-2 Serological Profile in Healthcare Professionals of a Southern Italy Hospital
Carlo, A. D., Caputo, S. L., Paolillo, C., Rosa, A. M., D’Orsi, U., Palma, M. D., Reveglia, P., Lacedonia, D., Cinnella, G., Barbaro, M. P. F., et al. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17249324 · Cited by 15
Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut
Papasavas, P. K., Olugbile, S. O., Wu, U., Robinson, K. J., Roberts, A. L., O’Sullivan, D. M., McLaughlin, T., Mather, J., Steinberg, A. C., Orlando, R., et al. (2021) · Journal of Hospital Infection · doi:10.1016/j.jhin.2021.04.021 · Cited by 13
Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a University Hospital at Tokyo
Igawa, G., Ai, T., Yamamoto, T. S., Ito, K., Nojiri, S., Saito, K., Wakita, M., Fukuda, H., Hori, S., Misawa, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12809-x · Cited by 15
Low prevalence of antibodies against SARS‐CoV‐2 among voluntary blood donors in Guangzhou, China
Xu, R., Huang, J., Duan, C., Liao, Q., Shan, Z., Wang, M., Xia, R., Li, C., Fu, Y., & Wang, H. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26445 · Cited by 14
Personnel protection strategy for healthcare workers in Wuhan during the COVID-19 epidemic
Hou, F. F., Zhou, F., Xu, X. P., Wang, D. W., Xu, G., Jiang, T., Nie, S., Wu, X., Ren, C., Wang, G., et al. (2020) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaa024 · Cited by 14
Self-citation
The Risk of SARS-CoV-2 Infection among Healthcare Workers
Madran, B., Keske, Ş., Besli, Y., Bozkurt, I., & Ergönül, Ö. (2020) · Infectious Diseases and Clinical Microbiology · doi:10.36519/idcm.2020.0019 · Cited by 14
Expectile depth: Theory and computation for bivariate datasets
Cascos, I., & Ochoa, M. (2021) · Journal of Multivariate Analysis · doi:10.1016/j.jmva.2021.104757 · Cited by 14
SARS-CoV2 IgG antibody: Seroprevalence among health care workers
Prakash, O., Solanki, B., Sheth, J. K., Makwana, G., Kadam, M., Vyas, S., Shukla, A. A., Pethani, J., & Tiwari, H. (2021) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2021.100766 · Cited by 14
Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA
Samore, M. H., Looney, A., Orleans, B., Greene, T., Seegert, N., Delgado, J. C., Presson, A. P., Zhang, C., Ying, J., Zhang, Y., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2711.204435 · Cited by 14
Seroepidemiology of SARS-CoV-2 infections in an urban population-based cohort in León, Nicaragua
González, F., Vielot, N. A., Sciaudone, M., Toval-Ruíz, C., Premkumar, L., Gutiérrez, L., Centeno, E., Munguia, N., Blandón, P., de Silva, A. M., et al. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002144 · Cited by 15
Seroprevalence of SARS‐CoV‐2 among high‐density communities and hyper‐endemicity of COVID‐19 in Vietnam
Hoang, V. T., Pham, D. T., Nguyen, Q. T., Nguyen, D. C., Nguyen, D. T., Nguyen, T. B., Tran, T. K. T., Phan, T. L., Vo, P. L. N., Dao, T. L., et al. (2022) · Tropical Medicine & International Health · doi:10.1111/tmi.13744 · Cited by 14
Seroprevalence Surveys for Anti-SARS-CoV-2 Antibody in Different Populations in Taiwan With Low Incidence of COVID-19 in 2020 and Severe Outbreaks of SARS in 2003
Tseng, W.-P., Wu, J.-L., Wu, C., Kuo, K., Lin, C., Chung, M., Lee, Y.-F., Yang, B., Huang, C., Chen, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626609 · Cited by 14
Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown
Breyer, M., Breyer‐Kohansal, R., Hartl, S., Kundi, M., Weseslindtner, L., Stiasny, K., Puchhammer‐Stöckl, E., Schrott, A., Födinger, M., Binder, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89711-5 · Cited by 14
Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19
Chen, J., Huang, R., Nie, Y., Wen, X., & Wu, Y. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00327-x · Cited by 12
Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology
Ochola, L. B., Ogongo, P., Mbugua, S. M., Gitaka, J., & Suliman, S. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.005 · Cited by 13
Seroprevalence of the SARS-CoV-2 antibody in healthcare workers: a multicentre cross-sectional study in 10 Colombian cities
Malagón-Rojas, J., Mercado, M., Toloza-Pérez, Y. G., Parra-Barrera, E. L., Palma, M., Muñoz, E., López, R., Almentero, J., Rubio, V. V., Ibáñez, E., et al. (2021) · Occupational and Environmental Medicine · doi:10.1136/oemed-2021-107487 · Cited by 13
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in hospitalized patients at a tertiary referral center in North IndiaPreprint
Ray, A., Singh, K., Chattopadhyay, S., Mehdi, F., Batra, G., Gupta, A., Agarwal, A., Bhavesh, M., Sahni, S., Chaithra, R., et al. (2020) · medRxiv · doi:10.1101/2020.08.22.20179937 · Cited by 13
Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives
Koma, T., Adachi, S., Doi, N., Adachi, A., & Nomaguchi, M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.02016 · Cited by 13
Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan
Smagul, M., Yesmagambetova, A., Nusupbaeva, G., Kirpicheva, U., Kasabekova, L. K., Nukenova, G., Saliev, T. M., Fakhradiyev, I. R., Tanabayeva, S. B., & Zhussupov, B. (2022) · Health Science Reports · doi:10.1002/hsr2.562 · Cited by 12
Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers
Fong, D., Nicolò, K. O. S., Alber, M., & Mitterer, M. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-020-01807-6 · Cited by 12
Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study
Ristić, M., Milosavljević, B., Vapa, S., Marković, M., & Petrović, V. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254516 · Cited by 12
The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera
Li, G., Zhou, Z., Du, P. F., Yu, M., Li, N., Xiong, X., Huang, H., Liu, Z., Dai, Q., Zhu, J., et al. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab016 · Cited by 12
Self-citation
Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola
Sebastião, C. S., Galangue, M., Gaston, C., Van‐Dunen, R., Quivinja, J., Lunbungululo, E., Alfredo, D., Sozinho, A., Teixeira, A., Manico, E., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06814-0 · Cited by 12
Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community
Guarino, C., Larson, E. M., Babasyan, S., Rollins, A., Joshi, L. R., Laverack, M. A., Parrilla, L., Plocharczyk, E. F., Diel, D. G., & Wagner, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262868 · Cited by 12
The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients
Xu, X. P., Nie, S., Sun, J., Kong, Y., Liang, M., Li, D., Ma, T., Peng, J., Gao, S., Shao, Y., et al. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.07.010 · Cited by 12
Self-citation
Early and Longitudinal Humoral Response to the SARS-CoV-2 mRNA BNT162b2 Vaccine in Healthcare Workers: Significance of BMI, Adipose Tissue and Muscle Mass on Long-Lasting Post-Vaccinal Immunity
Golec, M., Fronczek, M., Zembala-John, J., Chrapiec, M., Konka, A., Wystyrk, K., Botor, H., Brzoza, Z., Kasperczyk, S., & Bułdak, R. J. (2022) · Viruses · doi:10.3390/v14050868 · Cited by 13
Analysing Long-Term Socio-Economic Impacts of COVID-19 across Diverse African ContextsPreprint
Böhl, D., Burrows, M. J., Hughes, B. B., Keller, B., & Swaden, D. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3941481 · Cited by 12
The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients
Xu, X. P., Nie, S., Sun, J., Kong, Y., Liang, M., Li, D., Ma, T., Peng, J., Gao, S., Shao, Y., et al. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.07.022 · Cited by 11
Self-citation
Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures
Gonçalves, J., Sousa, R., Jacinto, M. J., Amaral-Silva, D., Paula, F. S., de Sousa, R. D., Zahedi, S., Carvalho, J. A., Cabral, M. G., Costa, M., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.603996 · Cited by 9
SARS-CoV-2 PCR positivity rate and seroprevalence of related antibodies among a sample of patients in Cairo: Pre-wave 2 results of a screening program in a university hospital
Girgis, S. A., Hafez, H. M., Elarab, H. E., Sherif, B., Sabry, M. H., Afifi, I., Hassan, F. E., Reda, A., Elsayed, S., Mahmoud, A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254581 · Cited by 12
Needs, Challenges and Countermeasures of SARS-CoV-2 Surveillance in Cold-Chain Foods and Packaging to Prevent Possible COVID-19 Resurgence: A Perspective from Advanced Detections
Li, Y., Qiao, J., Han, X., Zhao, Z., Kou, J., Zhang, W., Man, S., & Ma, L. (2022) · Viruses · doi:10.3390/v15010120 · Cited by 11
Time‐dependent changes in the seroprevalence of COVID‐19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID‐19
Suda, G., Ogawa, K., Kimura, M., Maehara, O., Kitagataya, T., Ohara, M., Tokuchi, Y., Kubo, A., Yamada, R., Shigesawa, T., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13551 · Cited by 11
Sensitivity and specificity of 14 SARS-CoV-2 serological assays and their diagnostic potential in RT-PCR negative COVID-19 infections
Honacker, E. V., Coorevits, L., Boelens, J., Verhasselt, B., Braeckel, E. V., Bauters, F. A., Bus, L. D., Schelstraete, P., Willems, J., Vandendriessche, S., et al. (2020) · Acta Clinica Belgica · doi:10.1080/17843286.2020.1861885 · Cited by 11
SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes
Garay, E., Coll, H. A. S., Rivero, R., Gastelbondo, B., Faccini‐Martínez, Á. A., Berrocal, J., Perez, A. G., Badillo, M., Martínez, C., Botero, Y., et al. (2021) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trab094 · Cited by 11
Risk Groups for SARS-CoV-2 Infection among Healthcare Workers: Community Versus Hospital Transmission
Pınarlık, F., Genç, Z., Tekin, S., Kapmaz, M., & Ergönül, Ö. (2021) · Infectious Disease Reports · doi:10.3390/idr13030067 · Cited by 11
Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional studyPreprint
Ling, R., Yu, Y., He, J., Zhang, J., Xu, S., Sun, R., Zhu, W., Chen, M., Li, T., Ji, H., et al. (2020) · medRxiv · doi:10.1101/2020.06.16.20132423 · Cited by 11
Designing and Interpreting Coronavirus Disease 2019 (COVID-19) Diagnostics: Mathematics, Visual Logistics, and Low Prevalence
Kost, G. J. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0443-sa · Cited by 9
SARS-CoV-2 infection prevalence on repatriation flights from Wuhan City, China
Thompson, H. A., Imai, N., Dighe, A., Ainslie, K. E. C., Baguelin, M., Bhatia, S., Bhatt, S., Boonyasiri, A., Boyd, O., Brazeau, N. F., et al. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa135 · Cited by 10
SARS‐CoV‐2 and COVID‐19 for the ophthalmologist
Brandão‐de‐Resende, C., Diniz‐Filho, A., Brito, F. D. A., & Vasconcelos-Santos, D. V. (2020) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13877 · Cited by 10

Authors: Xu, X., Sun, J., Nie, S., Li, H., Kong, Y., Liang, M., Hou, J., Huang, X., Li, D., Ma, T., Peng, J., Gao, S., Shao, Y., Zhu, H., Lau, J. Y.-N., Wang, G., Xie, C., Jiang, L., Huang, A., Yang, Z., Zhang, K., & Hou, F. F.
Affiliations: Nanfang Hospital (CN)
Kingmed Diagnostics (CN)
First People's Hospital of Foshan (CN)
Honghu People’s Hospital (CN)
First People's Hospital of Jingzhou (CN)
Jingzhou Central Hospital (CN)
Honghu Hospital of Traditional Chinese Medicine (CN)
Hong Kong Polytechnic University (HK)
Tsinghua University (CN)
University of Electronic Science and Technology of China (CN)
Chongqing Medical University (CN)
Macau University of Science and Technology (MO)
Corresponding author: Huang, Ailong
Yang, Zhenglin
Zhang, Kang
Hou, Fan Fan
ORCID: Xu, Xin
Sun, Jian
Nie, Sheng
Li, Huiyuan
Kong, Yaozhong
Liang, Min
Hou, Jinlin
Li, Dongfeng
Ma, Tean
Shao, Yong
Zhu, Hong
Wang, Guangyu
Xie, Chunbao
Jiang, Li
Huang, Ailong
Yang, Zhenglin
Zhang, Kang
Hou, Fan Fan
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 2020-06-05
Volume: 26
Issue: 8
Pages: 1193-1195
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/s41591-020-0949-6
OpenAlex: W3033219406
Cited by: 405
References: 14
Citations by year: 2026: 2 · 2025: 9 · 2024: 16 · 2023: 28 · 2022: 58 · 2021: 174 · 2020: 118
FWCI: 12.42
Type: journal article
Language: en
Update notices: correction (2020-08-18)
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Fundo para o Desenvolvimento das Ciências e da Tecnologia (0035/2020/A)
Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2020GZR110306001, 2018GZR110102004, 2018GZR0201003)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords: SARS-CoV-2, COVID-19 pandemic, seroprevalence, immunoglobulin M, IgG, serological surveillance, asymptomatic infection, Wuhan, hemodialysis patients, healthcare workers, regional variation
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, Antibodies, Viral, China, Female, Health Personnel, Humans, Immunoglobulin G, Immunoglobulin M, Male, Middle Aged, Pneumonia, Viral, Seroepidemiologic Studies, Coronavirus Infections, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks